Eirion Therapeutics to Present at the 2024 IMCAS WORLD CONGRESS
WOBURN, Mass., Oct. 17, 2022 /PRNewswire/ -- Eirion Therapeutics Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial for the treatment of glabellar wrinkles using the next generation, ready-to-use liquid injectable neuromodulator AI-09. The double-blind, placebo-controlled, dose escalation study is designed to determine the safety and optimal dose level of AI-09. The study is expected to recruit approximately 72 subjects. The study has been initiated at Baumann Cosmetic Dermatology in Miami, Florida by Leslie Baumann, MD, a leading clinical investigator in the field of aesthetic neuromodulators.
Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer.